Oral paclitaxel

DRUG2 trials

Sponsors

Daehwa Pharmaceutical Co., Ltd., Tianjin Medical University Cancer Institute and Hospital

Conditions

Breast CancerRecurrent or Metastatic Breast Cancer

Phase 2

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruitingNCT03315364

Daehwa Pharmaceutical Co., Ltd.Recurrent or Metastatic Breast Cancer

Start: 2017-12-18End: 2028-11-30Updated: 2026-04-01

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Not yet recruitingNCT07441486

Tianjin Medical University Cancer Institute and HospitalBreast Cancer

Start: 2026-04-01End: 2026-08-30Target: 50Updated: 2026-03-02

Related Papers

Phase III of oral paclitaxel (DHP107) vs intravenous paclitaxel in HER2-negative recurrent or metastatic breast cancer (mBC): Primary analysis of a multinational optimal trial (NCT03315364).

Journal of Clinical Oncology2025-05-281 citations

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Therapeutic Advances in Medical Oncology2021-01-0112 citations

[OPTIMAL 3] A phase III trial to evaluate the efficacy and safety of DHP107 (Liporaxel, oral paclitaxel) compared to Taxol (IV paclitaxel) as first line therapy in patients with recurrent or metastatic HER2 negative breast cancer (BC) (NCT03315364).

Journal of Clinical Oncology2020-05-208 citations